Promacta (eltrombopag)

P2, N=25, Suspended, Abhay Singh, MD MPH | Recruiting --> Suspended

Cyclosporine A (CsA) functions as a calcineurin inhibitor that perturbs T cell activation via calcineurin-nuclear factor of activated T cells (CaN-NFAT) signaling inhibitors, establishing its central role in hematological therapeutics. The manuscript further elaborates on pharmacological synergies between CsA and novel targeted agents including eltrombopag, ruxolitinib, and immune checkpoint inhibitors, while evaluating its capacity to surmount chemotherapeutic resistance and function as a bridging modality to CAR-T cell infusion. Lastly, we propose tiered management protocols for dose-limiting toxicities (nephrotoxicity and hypertension) and highlight emerging research frontiers in nanoformulation and artificial intelligence-guided therapeutic drug monitoring.

P=N/A, N=150, Not yet recruiting, Novartis Pharmaceuticals

P2, N=164, Recruiting, Novartis Pharmaceuticals | Trial completion date: Sep 2030 --> Mar 2027 | Initiation date: Jun 2026 --> Nov 2026 | Trial primary completion date: Dec 2028 --> Mar 2027

P2, N=164, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting | Trial completion date: Mar 2030 --> Sep 2030 | Trial primary completion date: Jun 2028 --> Dec 2028

P4, N=224, Recruiting, Institute of Hematology & Blood Diseases Hospital, China | Trial completion date: Aug 2022 --> Aug 2030 | Trial primary completion date: Feb 2022 --> Feb 2029

Among patients with SAA treated with IST-EPAG, early and late patterns of clonal evolution to myeloid cancer were observed: Chromosome 7 abnormalities occurred within 1 year, whereas later events (4-5 years) involved stepwise mutation acquisition in preexisting ASXL1- or U2AF1-mutated clones.

P2, N=34, Completed, National Heart, Lung, and Blood Institute (NHLBI) | Active, not recruiting --> Completed | Trial completion date: Jun 2025 --> Jan 2026

We diagnosed the patient with moderately severe AA and observed hematopoietic recovery following treatment with anabolic steroids and eltrombopag...Cyclosporine and romiplostim treatment were effective, allowing for outpatient management. In the two cases described herein, a small number of PNH-phenotype cells were confirmed. The clinical importance of the small PNH-phenotype populations and the mechanism underlying AA during OSIM therapy remain unclear and warrant further investigation.

P2, N=164, Not yet recruiting, Novartis Pharmaceuticals | Trial completion date: Aug 2030 --> Mar 2030 | Trial primary completion date: Dec 2028 --> Jun 2028

P2, N=174, Recruiting, Associazione Qol-one | Not yet recruiting --> Recruiting

P=N/A, N=112, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China